109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
从哮喘进展为系统性嗜酸性肉芽肿性多血管炎的临床、生物标志物及影像学变化：一项回顾性队列研究
Authors Lu C, Ou C, Deng Y, Li N, Ma Y, Luo J, Zhou J, Chung KF, Deng Z, Zhang Q
Received 10 June 2025
Accepted for publication 22 October 2025
Published 11 November 2025 Volume 2025:18 Pages 1615—1626
DOI https://doi.org/10.2147/JAA.S542255
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Luis Garcia-Marcos
Chenyang Lu,1,* Changxing Ou,1,* Yu Deng,2,* Na Li,3,* Yuwen Ma,1 JinXi Luo,1 Jiaxuan Zhou,2 Kian Fan Chung,4 Zhenan Deng,1 Qingling Zhang1,5
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 2Department of Radiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 3Department of Pulmonary and Critical Care Medicine, Shenzhen Longgang Central Hospital, Shenzhen, Guangdong, People’s Republic of China; 4National Heart and Lung Institute, Imperial College London, London SW3, UK; Royal Brompton and Harefield Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London SW3, UK; 5Guangzhou National Laboratory, Bioland, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qingling Zhang, Email qingling@gird.cn Zhenan Deng, Email drdengza@163.com
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multi-organ autoimmune disease characterized by eosinophilic infiltration of peripheral blood and tissues, and necrotizing granulomatous inflammation of small and medium-sized blood vessels. In the prodromal stage of EGPA, patients may present with features of refractory asthma, with the involvement of other organs occurring later when the diagnosis of EGPA is made. The difficulty of early diagnosis makes treatment difficult.
Methods: We retrospectively describe patients (N=13) who attended the asthma clinic at the First Affiliated Hospital of Guangzhou Medical University between 2008 and 2024. The disease course was categorized into three stages: asthma, lung-limited or lung-dominant EGPA (L-EGPA), and systemic EGPA (S-EGPA). Patients with severe eosinophilic asthma served as controls. We evaluated baseline demographic, as well as organ involvement, complication, laboratory findings, lung function, high-resolution computed tomography (HRCT), and treatment across different disease stages. A case–crossover design and Bayesian conditional logistic regression were employed to evaluate the impact of medication use on disease progression.
Results: We identified a group of EGPA patients who exhibited consistent disease progression to transit from asthma to L-EGPA, and eventually to S-EGPA. These stages exhibit distinct clinical and imaging features, with significantly elevated eosinophilic inflammatory markers in induced sputum or blood being a hallmark of L-EGPA. This distinction may aid in differentiating refractory asthma from L-EGPA.
Conclusion: In conclusion, the L-EGPA phase may represent a distinct stage in EGPA development that is often challenging to distinguish from refractory asthma. Characterizing this phase and identifying specific biomarkers could facilitate earlier diagnosis and treatment, potentially improving patient outcomes—a hypothesis that warrants further validation.
Keywords: eosinophilic granulomatosis with polyangiitis, asthma, eosinophilia, rare pulmonary diseases
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 2Department of Radiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 3Department of Pulmonary and Critical Care Medicine, Shenzhen Longgang Central Hospital, Shenzhen, Guangdong, People’s Republic of China; 4National Heart and Lung Institute, Imperial College London, London SW3, UK; Royal Brompton and Harefield Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London SW3, UK; 5Guangzhou National Laboratory, Bioland, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qingling Zhang, Email qingling@gird.cn Zhenan Deng, Email drdengza@163.com
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multi-organ autoimmune disease characterized by eosinophilic infiltration of peripheral blood and tissues, and necrotizing granulomatous inflammation of small and medium-sized blood vessels. In the prodromal stage of EGPA, patients may present with features of refractory asthma, with the involvement of other organs occurring later when the diagnosis of EGPA is made. The difficulty of early diagnosis makes treatment difficult.
Methods: We retrospectively describe patients (N=13) who attended the asthma clinic at the First Affiliated Hospital of Guangzhou Medical University between 2008 and 2024. The disease course was categorized into three stages: asthma, lung-limited or lung-dominant EGPA (L-EGPA), and systemic EGPA (S-EGPA). Patients with severe eosinophilic asthma served as controls. We evaluated baseline demographic, as well as organ involvement, complication, laboratory findings, lung function, high-resolution computed tomography (HRCT), and treatment across different disease stages. A case–crossover design and Bayesian conditional logistic regression were employed to evaluate the impact of medication use on disease progression.
Results: We identified a group of EGPA patients who exhibited consistent disease progression to transit from asthma to L-EGPA, and eventually to S-EGPA. These stages exhibit distinct clinical and imaging features, with significantly elevated eosinophilic inflammatory markers in induced sputum or blood being a hallmark of L-EGPA. This distinction may aid in differentiating refractory asthma from L-EGPA.
Conclusion: In conclusion, the L-EGPA phase may represent a distinct stage in EGPA development that is often challenging to distinguish from refractory asthma. Characterizing this phase and identifying specific biomarkers could facilitate earlier diagnosis and treatment, potentially improving patient outcomes—a hypothesis that warrants further validation.
Keywords: eosinophilic granulomatosis with polyangiitis, asthma, eosinophilia, rare pulmonary diseases